Princeton, NJ, October 24, 2024 - PRISM MediaWire - Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other...
NEWSROOM
biotechnology
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
PITTSBURGH, Oct. 09, 2024 - PRISM MediaWire - Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024. Event: Lipella Presentation - 2024 Maxim Healthcare Virtual Summit Date: Thursday, October 17th, 2024...
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System Jackson Center, PA, October 1, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation....
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development New York, NY, September 30, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific...
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). The Company reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with...
Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Early Pilot Study Data from Veteran Volunteers is Compelling - Part B Jackson Center, PA September 9, 2024 – PRISM MediaWire - Halberd Corporation (OTC: HALB) today issued the following letter to its shareholders: We hope you have had an opportunity to check out last week’s Press release, Part A. This Part B supplements that release of a few days ago. As always reach out to us if you have any comments or thoughts. Good or bad, we appreciate them! The PTSD market is evolving. It is also...
Aclarion Added to PRISM Emerging Medical Devices Index
Company's industry-first technology addresses chronic low back pain Aclarion secured its first commercial agreement with Michigan's Sheridan Community Hospital PRISM Emerging Medical Devices Index features companies at forefront of innovation and market disruption in medtech NEW YORK, September 06, 2024 – PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index,...
Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
Company will use novel, patented Klotho Gene (s-KL) in studies New York, NY, September 4, 2024 - PRISM MediaWire - ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer’s and...
BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
Advanced wound care MedTech company recently reported a record second-quarter with $116.4M in revenue for H1, 2024 POMPANO BEACH, Fla., Aug. 29, 2024 -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, will present at the H.C. Wainwright 26th Annual Global Investment Conference held on September 9th through 11th in New York City at the Lotte Palace Hotel....
Halberd Corp. Issues Letter to Shareholders
JACKSON CENTER, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) today issued the following letter to its shareholders: Halberd Corp. - Taking a Moment to Recenter Our Technical Progress Introducing Tri-ax™ TBI Nasal Spray Treatment- the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal This is the first of a series of three significant Press Releases we plan to issue shortly. Many of our investors have been voicing...
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW’s balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in...
ANEW MEDICAL, INC. Appoints New CFO
New York, NY, August 19, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company’s Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged. “Jeff LeBlanc is a highly experienced senior executive, and we...
ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS
Patents issued in mainland China protect the Company’s novel secreted Klotho protein and Its gene delivery system Recent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer’s Disease and other neurodegenerative diseases New York, NY, August 8, 2024 - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the...
Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
Jackson Center, PA July 24, 2024 – Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-AxTM nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. Dr. Russell Carr, the project's Principal Investigator, commented: “In the early stages of our Phase II studies, we focused on assessing the efficacy of our innovative Tri-AxTM nasal spray in...
Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines
Phytanix Bio is a preclinical stage pharmaceutical company founded by former members and associates of GW Pharmaceuticals, holding exclusive cannabinoid and cannabinoid-like medicine intellectual property (IP) The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal close The business combination is expected to be...
ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments
Genomics data suggests having an active Klotho gene sequence may help people live longer, healthier lives The Company was granted patents in Europe, China, and Hong Kong and awaits issuance of patents in the U.S. and Canada NEW YORK, July 9, 2024 -- ANEW MEDICAL, INC. (NASDAQ: WENA) (“ANEW”), a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders, announces plans to advance its recently patented Klotho gene...
ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene
Collaboration focuses on research and development of ANEW’s patented Klotho gene therapy in enhancing longevity and reducing age-related diseases ANEW’s mission is to deliver transformative protein, cell, and gene therapies in areas of high unmet medical needs, particularly targeting highly prevalent neurodegenerative diseases and age-related disorders NEW YORK, June, 27. 2024 -- ANEW MEDICAL, INC. (Nasdaq: WENA), a biopharmaceutical company specializing in the advancement of novel...
Rodedawg (OTC: RWGI) Launches TikTok Shop to Expand into Global E-Commerce Market
Company E-commerce Effort Expands into 10 Billion Dollar Marketplace COSTA MESA, CA, June 12th, 2024 – Rodedawg International Industries, Inc. (OTC: RWGI), a prominent cannabis manufacturer and distributor, is excited to announce the launch of its own TikTok Shop. This strategic move aims to leverage the booming e-commerce potential on TikTok, expanding Rodedawg's market reach and driving sales of its popular product lines. The initial product offering is the All natural Elixicure Topical Pain...
SIPP Industries Announces Strategic R&D Agreement with Calypso Pharmaceuticals to Develop Nano-Emulsified Topical Targeting Melanoma
Costa Mesa, CA, June 11, 2024 - SIPP Industries, Inc. (OTC: SIPC), a multifaceted corporation specializing in the manufacturing and distribution of commercial and consumer products in the cannabis industry, is pleased to announce a Research and Development agreement with Calypso Pharmaceuticals. The aim is to create a nano-emulsified topical formulation in collaboration with AVEINA, SIPP's wellness-focused brand specializing in nanotechnology formulations, to target melanoma using Peptide...
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Conference Call on Wednesday, May 15, 2024, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, CA, May 15, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc. On track to ship research use only (RUO) GraftAssureTM transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD...
Oncocyte to Announce First Quarter 2024 Financial Results
Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, CA, May 13, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested parties...
ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS
Conference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, April 12, 2024 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad Laboratories, Inc. commercial partnership for transplant monitoring IP $15.8 million in gross proceeds received from private placement offering $4.4 million and $3.8 million Q4 2023 and est. Q1 2024 cash burn, respectively...
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
IRVINE, CA, April 11, 2024 - Oncocyte Corporation (NASDAQ: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “Purchase Agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purchase price of $2.9163 per pre-funded warrant...
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, CA, April 11, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the...
ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Conference Call and Webcast on Friday, April 12, 2024, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, April 09, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial...
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico
IRVINE, CA, January 16, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico.srax.com/ About...
PRISM MarketView Honors National Biotechnology Month with a Spotlight on Emerging Biotech Innovators
New York, N.Y., January 9, 2024 - In celebration of National Biotechnology Month, PRISM MarketView acknowledges the significant advancements in biotechnology since its establishment by President Clinton in 2000. This month-long celebration underscores the remarkable achievements and untapped potential of biotechnology – a field that harnesses living organisms and systems to develop pioneering products, intersecting with various scientific disciplines. Biotechnology, with its deep roots in...
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
Significant unmet need for regulated product in $2B US testing market Opportunity for expedited pathway for kitted product in development IRVINE, CA, December 06, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests (LDTs) to seek regulatory approval. This move positions Oncocyte within the recent...
Oncocyte Reports Third Quarter 2023 Financial Results
-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, CA, November 09, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial revenue is...
Oncocyte to Announce Third Quarter 2023 Financial Results
Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, November 3, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issued the same day,...